Rectal swab detection of ESBL, carbapenemases, and high-level cephalosporinase to predict C3G-resistant Enterobacteriaceae infections in ICU patients
Official title: Predictive Value of a Rectal Swab With Detection of Enterobacteria (ESBL-E), Carbapenemases, and High-level Cephalosporinase (HLC) on the Risk of Infections With C3G-resistant Enterobacteria in Intensive Care
Run by University Hospital, Strasbourg, France · NCT07345923 · Data updated 2026-11-12
This study tests whether a rectal swab that finds ESBL, carbapenemases, or high-level cephalosporinase can predict which adult ICU patients at Strasbourg are likely to get C3G-resistant Enterobacteriaceae infections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | October 6, 2025 |
| Main results expected | April 2027 |
| Study ends | April 2027 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT07345923 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult medical or surgical ICU patients at Strasbourg University Hospitals who underwent rectal screening for ESBL/HLC/carbapenemase carriage between January 1, 2024 and January 1, 2025.
✕Probably not a fit
Patients who were not screened with a rectal swab, were treated outside the specified ICUs or time window, were under 18, or who carry organisms not covered by these markers are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational cohort of adult medical and surgical ICU patients at Strasbourg University Hospitals who had rectal screening for ESBL/HLC/carbapenemase carriage between January 1, 2024 and January 1, 2025. Investigators will link colonization results from rectal swabs to subsequent clinical and microbiology records to identify infections with C3G-resistant Enterobacteriaceae. No experimental interventions are given; the study analyzes existing diagnostic and outcome data to estimate predictive value. Findings aim to quantify how well carriage detected by rectal swab forecasts later resistant infections in this ICU population.
Why it matters
Potential benefit: If successful, the test could help identify ICU patients at high risk for resistant enterobacterial infections so clinicians can tailor empiric antibiotics and infection-control measures.
How similar studies have gone: Previous observational studies have shown that rectal carriage of ESBL- and carbapenemase-producing Enterobacteriaceae often predicts subsequent infection, though predictive accuracy varies by setting and the role of high-level cephalosporinase markers is less well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 18 years old) * Who have been in medical or surgical intensive care at Strasbourg University Hospitals (between January 1, 2024, and January 1, 2025) * Who have undergone rectal screening for carriage of ESBL/HLC/carbapenemase-producing Enterobacteriaceae Exclusion Criteria: * Refusal to participate in the study
Where it's running
-
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: baptiste Hoellinger, MD
- Email: baptiste.hoellinger@chru-strasbourg.fr
- Phone: 33 3 69 55 05 45
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aztreonam-Avibactam in Immunocompromised Patients with Multidrug-Resistant Infections
This study tests how well and how safely aztreonam-avibactam works in adults with weakened immune systems who have highly resistant Enterobacterales infections.
-
Using fecal microbiota transplantation to eliminate drug-resistant bacteria from the gut
This study is testing whether a treatment called fecal microbiota transplantation can help people get rid of tough drug-resistant bacteria in their gut.
-
Using fecal transplantation to eliminate drug-resistant bacteria
This study is testing whether using fecal transplants can help adults get rid of harmful drug-resistant bacteria in their gut.
-
Using fecal microbiota transplantation to treat antibiotic-resistant infections
This study is testing whether a treatment using healthy gut bacteria from donors can help people get rid of hard-to-treat infections caused by antibiotic-resistant germs.
-
Comparing two antibiotics for treating bloodstream infections from resistant bacteria
This study is testing if a new antibiotic called piperacillin-tazobactam works as well as meropenem for treating bloodstream infections caused by resistant bacteria in adults.
-
Jet versus vibrating mesh inhalation of polymyxin B for ventilated patients with carbapenem‑resistant Gram‑negative pneumonia
This trial tests whether jet nebulizers or vibrating mesh nebulizers deliver inhaled polymyxin B more effectively for mechanically ventilated patients with carbapenem‑resistant Gram‑negative pneumonia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.